Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by sury – India, 2019-04-05 06:36  – Posting: # 20122
Views: 921

Thanks for your reply.....but i have few more doubts on this

Can we use the pharmacokinetic parameter ISCV for the sample size estimation for the clinical endpoint bioequivalence study?
is it will be in accordance with the regulatory requirement?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,882 posts in 4,214 threads, 1,365 registered users;
online 18 (1 registered, 17 guests [including 9 identified bots]).
Forum time (Europe/Vienna): 17:08 CEST

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5